SALT LAKE CITY, Nov. 3, 2016 /PRNewswire/ -- DiscGenics, Inc. (DiscGenics) announces the allowance of 9 additional patents that expand its intellectual property portfolio within both the U.S. and globally to 24 issued patents. The new patents include 2 in the U.S. and 7 in key European markets.
The patent portfolio provides coverage on its proprietary culture process and novel Discogenic Cell technology that is the therapeutic agent within its first product, Injectable Discogenic Cell Therapy (IDCT). The company is currently in the process of completing its preclinical development and looks forward to initiating initial human clinical trial during 2017 pending regulatory approvals.
About DiscGenics, Inc.
DiscGenics is a privately funded biotechnology company developing advanced spinal stem cell therapeutics to treat patients with diseases of the intervertebral disc. News and other information are available at: http://www.DiscGenics.com.
Bob Wynalek, Chief Operating and Commercialization Officer